Research

Hormonal

Somatostatin infusion suppresses hyperglucagonemia and markedly reduces hyperglycemia in Type 1 Diabetic humans, even when insulin is reduced or discontinued.

In humans, suppressing glucagon with somatostatin lowers blood sugar even with low insulin. This supports the idea that targeting glucagon is a viable therapeutic strategy, though somatostatin's side effects limit its use.

GoodSupportsHIGH confidence
When somatostatin was infused into... insulin-deprived humans with T1DM... hyperglucagonemia was suppressed and hyperglycemia was markedly decreased, even though insulin had been reduced or discontinued.
Roger H. Unger et al. · Journal of Clinical Investigation · 2012

Why this rating

Human studies confirm the mechanism, but long-term use is limited by side effects.

Source

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

Roger H. Unger et al. · Journal of Clinical Investigation · 2012

DOI 10.1172/jci60016

narrative_reviewCited 667×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →